Evaluation of myotonometry for myotonia, muscle stiffness and elasticity in neuromuscular disorders.

Journal Information

Full Title: J Neurol

Abbreviation: J Neurol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
5/6
83.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"all data are presented in table 2"

Code Sharing
Evidence found in paper:

"Declarations Conflicts of interestAll authors report no disclosures regarding this study. Outside of this context, SW and KG have received a research grant from the DGM—Deutsche Gesellschaft für Muskelkranke e.V. KG received travel or speaker Honoraria from Sanofi-Aventis Germany GmbH, Amicus Therapeutics and Kedrion. SW has served on advisory boards for Alexion Pharma, CSL Behring and Sanofi Genzyme GmbH. In addition, he received funding for travel or speaker Honoraria from Sanofi-Aventis Germany GmbH; Amicus Therapeutics; SH Glykogenose Gesellschaft; AbbVie Germany GmbH; Recordati Pharma GmbH; CSL Behring GmbH; Alexion Pharma GmbH; Desitin Germany; Akcea GmbH. Outside of this context, BS has served on advisory boards for Amicus, Argenex, Astellas, and Sanofi; he has undertaken contracted available research for Amicus, Astellas, Roche, DFG, Horizon 2022, AMDA USA, Marigold foundation CA; and has received speaker honoraria from Alexion and Kedrion. Ethical standardAll procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of the LMU Klinikum, Project No. 19-613. In addition, the protocol was registered on a public clinical trials registry (ClinicalTrials.gov Identifier NCT04411732). All persons gave their informed consent prior to their inclusion in the study. Conflicts of interest All authors report no disclosures regarding this study. Outside of this context, SW and KG have received a research grant from the DGM—Deutsche Gesellschaft für Muskelkranke e.V. KG received travel or speaker Honoraria from Sanofi-Aventis Germany GmbH, Amicus Therapeutics and Kedrion. SW has served on advisory boards for Alexion Pharma, CSL Behring and Sanofi Genzyme GmbH. In addition, he received funding for travel or speaker Honoraria from Sanofi-Aventis Germany GmbH; Amicus Therapeutics; SH Glykogenose Gesellschaft; AbbVie Germany GmbH; Recordati Pharma GmbH; CSL Behring GmbH; Alexion Pharma GmbH; Desitin Germany; Akcea GmbH. Outside of this context, BS has served on advisory boards for Amicus, Argenex, Astellas, and Sanofi; he has undertaken contracted available research for Amicus, Astellas, Roche, DFG, Horizon 2022, AMDA USA, Marigold foundation CA; and has received speaker honoraria from Alexion and Kedrion."

Evidence found in paper:

"Funding Open Access funding enabled and organized by Projekt DEAL."

Evidence found in paper:

"Fifty-two patients were enrolled and divided into five disease groups. Additionally, 21 healthy subjects were enrolled as a control group. All included patients were assessed at the neuromuscular centre Friedrich-Baur-Institute at the Ludwig-Maximilians University Munich, Germany. The study was approved by the ethics committee of the LMU university hospital, Project No. 19-613, and the protocol was registered on a public clinical trials registry (ClinicalTrials.gov Identifier NCT04411732). Declarations: Conflicts of interestAll authors report no disclosures regarding this study. Outside of this context, SW and KG have received a research grant from the DGM—Deutsche Gesellschaft für Muskelkranke e.V. KG received travel or speaker Honoraria from Sanofi-Aventis Germany GmbH, Amicus Therapeutics and Kedrion. SW has served on advisory boards for Alexion Pharma, CSL Behring and Sanofi Genzyme GmbH. In addition, he received funding for travel or speaker Honoraria from Sanofi-Aventis Germany GmbH; Amicus Therapeutics; SH Glykogenose Gesellschaft; AbbVie Germany GmbH; Recordati Pharma GmbH; CSL Behring GmbH; Alexion Pharma GmbH; Desitin Germany; Akcea GmbH. Outside of this context, BS has served on advisory boards for Amicus, Argenex, Astellas, and Sanofi; he has undertaken contracted available research for Amicus, Astellas, Roche, DFG, Horizon 2022, AMDA USA, Marigold foundation CA; and has received speaker honoraria from Alexion and Kedrion.: Ethical standardAll procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of the LMU Klinikum, Project No. 19-613. In addition, the protocol was registered on a public clinical trials registry (ClinicalTrials.gov Identifier NCT04411732). All persons gave their informed consent prior to their inclusion in the study. Ethical standard: All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of the LMU Klinikum, Project No. 19-613. In addition, the protocol was registered on a public clinical trials registry (ClinicalTrials.gov Identifier NCT04411732). All persons gave their informed consent prior to their inclusion in the study."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025